Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 food effect study in healthy volunteers
NCT03302078Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 120 hours and Maximum Measured Concentration of BI 1015550 in Plasma at 120 hours. Started Oct 2017; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT03302078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302078.